US Artificial Intelligence in Genomics Market Forecast to 2035
The US Artificial Intelligence in Genomics Market is experiencing rapid expansion as pharmaceutical companies, healthcare providers, and research institutions increasingly integrate artificial intelligence into genomic research and clinical applications. According to Dimension Market Research, the market is projected to reach USD 525.6 million in 2026 and grow to USD 15,359.3 million by 2035, registering a compound annual growth rate (CAGR) of 45.5% during 2026–2035. This growth reflects the rising importance of AI-powered genomic interpretation, personalized healthcare, and advanced biological data analytics across the United States.
Artificial intelligence in genomics combines machine learning, deep learning, natural language processing, and computational biology to analyze genetic information and identify meaningful biological patterns. With next-generation sequencing generating increasingly large datasets, AI-powered platforms are becoming essential for identifying genetic variations, predicting disease risks, and supporting therapeutic research. Growing investments in precision medicine, cloud computing, biotechnology innovation, and genomic data management are further strengthening the market. These developments are positioning AI as an important technology in the future of US healthcare and life sciences.
Get free sample of this report (with custom data option): https://dimensionmarketresearch.com/request-sample/us-artificial-intelligence-in-genomics-market/
US Artificial Intelligence in Genomics Market Snapshot
● 2026 market size: USD 525.6 million.
● 2035 projected market value: USD 15,359.3 million.
● 2026–2035 forecast CAGR: 45.5%.
● 2021–2025: Historical market assessment period.
● 2027–2035: Forecast data period covered by the report.
● Leading component: Software, with 62.4% share in 2026.
● Leading technology: Machine learning, with 48.7% share.
● Leading functionality: Genome sequencing, with 44.9% share.
● Leading application: Drug discovery and development, with 39.6% share.
● Leading end user: Pharmaceutical and biotech companies, with 46.3% share.
Market Research Findings
According to Dimension Market Research, the US Artificial Intelligence in Genomics Market is led by increasing demand for advanced genomic software, machine learning applications, and AI-powered drug discovery solutions. Software accounts for approximately 62.4% of the component segment in 2026, while machine learning represents 48.7% of the technology category. Genome sequencing leads functionality with an estimated 44.9% share. Drug discovery and development is the leading application, accounting for 39.6%, supported by pharmaceutical companies' growing use of AI for identifying therapeutic targets. Pharmaceutical and biotechnology companies also dominate end-user adoption with a 46.3% share. Diagnostics, deep learning, and healthcare provider integration offer additional growth opportunities.
Why Is the US Artificial Intelligence in Genomics Market Growing?
The growing volume of genomic information and increasing demand for personalized healthcare are central factors supporting market expansion. Traditional genomic analysis methods can require significant time and specialized expertise, particularly when processing large sequencing datasets. AI technologies help researchers automate data interpretation, recognize genetic patterns, and generate predictive insights more efficiently. Pharmaceutical companies are also adopting AI-powered genomics to improve drug target identification and optimize research workflows. Meanwhile, healthcare providers are increasingly interested in genomic diagnostics and individualized treatment strategies. Improvements in computing infrastructure, sequencing technologies, and data analytics are making these applications more commercially accessible throughout the United States.
Key Growth Drivers of the US Artificial Intelligence in Genomics Market
● Rising demand for personalized and precision medicine solutions.
● Growing adoption of next-generation sequencing technologies.
● Increasing investments in genomic research and biotechnology.
● Expanding use of AI in pharmaceutical drug discovery.
● Rising demand for early disease detection and genetic diagnostics.
● Advancements in cloud computing and genomic data analytics.
● Growing integration of machine learning into clinical workflows.
US Artificial Intelligence in Genomics Market Research Scope and Segment Analysis
The research report examines the US Artificial Intelligence in Genomics Market across five major categories: component, technology, functionality, application, and end user. This segmentation provides insight into revenue contributions, technology adoption, and emerging business opportunities. Software and drug discovery and development are particularly important because of their strong market positions and expanding applications across research and healthcare.
Software Segment Leads the Component Category
The software segment is projected to hold approximately 62.4% of the US Artificial Intelligence in Genomics Market in 2026. Its leading position reflects increasing demand for platforms capable of processing, interpreting, and managing complex genomic datasets. AI-based software supports sequence alignment, genetic variant identification, predictive analytics, and biological data interpretation. These capabilities are important for research institutions, pharmaceutical companies, and healthcare organizations that need reliable genomic insights. Cloud-based software solutions are further improving accessibility by reducing dependence on expensive on-premise computing infrastructure. As genomic sequencing volumes increase, software platforms are expected to remain essential to the development of AI-driven genomics applications.
● Component categories: Software and services.
● Key software applications: Sequence analysis, variant detection, and predictive analytics.
Drug Discovery and Development Leads the Application Segment
Drug discovery and development is expected to account for approximately 39.6% of the market in 2026. Pharmaceutical and biotechnology companies are increasingly using AI to identify potential drug targets, analyze disease-associated genetic variations, and improve research efficiency. Integrating genomic datasets with machine learning algorithms allows researchers to identify biological relationships and evaluate potential therapeutic approaches. These capabilities are particularly relevant to complex diseases, oncology, and rare genetic conditions. Diagnostics represents another important application, as AI-powered genomic interpretation supports disease identification and clinical decision-making. Growing demand for targeted therapies and improved diagnostic accuracy is expected to strengthen both application areas.
● Key applications: Drug discovery, diagnostics, precision medicine, and agricultural research.
● Emerging opportunities: Genetic disease prediction and personalized treatment planning.
Read more about this market: https://dimensionmarketresearch.com/report/us-artificial-intelligence-in-genomics-market/
US Artificial Intelligence in Genomics Market Dynamics
Market Trends: Cloud-Based Platforms and Automated Genomic Workflows
Cloud computing is becoming an important part of AI-powered genomics because organizations require scalable infrastructure to store and process increasingly large genomic datasets. Cloud-based platforms allow research institutions, laboratories, and healthcare providers to access advanced analytical capabilities without maintaining extensive local computing resources. They also facilitate collaboration between researchers and support more efficient data processing. Another important trend is the automation of genomic workflows. AI-powered systems can streamline sequencing analysis, variant interpretation, and reporting processes, reducing manual workloads and improving operational efficiency. These technologies are helping organizations accelerate research activities and strengthen the integration of genomic information into clinical applications.
Market Opportunities: Multi-Omics Integration and Government Support
Multi-omics integration presents an important opportunity for the US Artificial Intelligence in Genomics Market. By combining genomic information with proteomics, metabolomics, and other biological datasets, researchers can develop a more comprehensive understanding of disease mechanisms. AI algorithms can identify relationships across different biological data types, supporting biomarker discovery, therapeutic research, and personalized treatment development. Government support and research funding also contribute to market opportunities. Public-sector investments, collaborations with academic institutions, and private-sector innovation can encourage the development of new AI genomics platforms. Companies offering scalable analytics and integrated research solutions may benefit from the expanding demand for advanced genomic interpretation.
Market Challenges: Data Privacy and High Implementation Costs
Despite strong growth potential, the market faces challenges associated with infrastructure investment, technical expertise, and genomic data protection. AI-powered genomics platforms require advanced computing systems, secure storage facilities, and specialized professionals who understand both biological information and machine learning. These requirements can increase implementation costs, particularly for smaller healthcare organizations and research centers. Data privacy is another major concern because genomic information contains sensitive personal details. Organizations must address patient consent, secure data handling, regulatory compliance, and responsible information sharing. Managing these requirements can increase operational complexity and influence the speed of commercial adoption across the US healthcare ecosystem.
Regional and Country Outlook: United States
The research report focuses on the United States, where a developed biotechnology industry, established pharmaceutical companies, advanced healthcare infrastructure, and extensive genomic research activities support market expansion. Increasing adoption of precision medicine and AI-driven diagnostics is encouraging organizations to invest in advanced genomic analytics. Collaborations between technology companies, research institutions, and healthcare providers are also contributing to innovation.
● Country: United States.
● 2026 market value: USD 525.6 million.
● 2035 forecast market value: USD 15,359.3 million.
● 2026–2035 CAGR: 45.5%.
Key Competitor Companies in the US Artificial Intelligence in Genomics Market
The competitive landscape includes genomics technology providers, AI software developers, biotechnology companies, and major technology corporations. Market participants focus on product innovation, strategic partnerships, research and development, and the integration of advanced analytics into genomic platforms.
● Illumina
● Thermo Fisher Scientific
● Roche
● QIAGEN
● IBM
● Microsoft
● NVIDIA Corporation
● Intel Corporation
● Tempus Labs
● DNAnexus
● Fabric Genomics
● Deep Genomics
● Verge Genomics
● Freenome Holdings
● GRAIL
● 23andMe
● Invitae Corporation
● PathAI
● Data4Cure
Get 10% instant discount on report purchase:
Explore more similar report:
● Ai In Precision Medicine Market
● Japan Artificial Intelligence In Genomics Market
● Saudi Arabia Artificial Intelligence In Genomics Market
● Bioinformatics Services Market
● Cross Species Organ Transplantation Market
● Exosome Diagnostics And Therapeutics Market
FAQ's: US Artificial Intelligence in Genomics Market
1. What is the US Artificial Intelligence in Genomics Market size in 2026?
According to Dimension Market Research, the US market is projected to reach USD 525.6 million in 2026.
2. What is the projected US AI in Genomics Market value by 2035?
The market is expected to reach USD 15,359.3 million by 2035, reflecting substantial growth opportunities.
3. What is the CAGR of the US Artificial Intelligence in Genomics Market?
The market is projected to register a CAGR of 45.5% during the 2026–2035 forecast period.
4. Which component dominates the US AI in Genomics Market?
The software segment leads the component category, accounting for approximately 62.4% of the market in 2026.
5. Which technology holds the largest market share?
Machine learning leads the technology segment with an estimated 48.7% market share in 2026.
6. Which application dominates the US Artificial Intelligence in Genomics Market?
Drug discovery and development leads the application segment with a projected 39.6% share in 2026.
7. What are the major growth drivers of the US AI genomics industry?
Precision medicine, sequencing advancements, genomic research investments, and AI-powered drug discovery are major growth drivers.
8. What are the key challenges facing the US AI in Genomics Market?
High implementation costs, infrastructure requirements, genomic data privacy, and regulatory compliance are significant challenges.
9. Who are the major players in the US Artificial Intelligence in Genomics Market?
Major companies include Illumina, Thermo Fisher Scientific, Roche, QIAGEN, NVIDIA, Microsoft, Tempus Labs, and DNAnexus.
10. What are the emerging opportunities in the US AI genomics industry?
Multi-omics integration, AI-assisted diagnostics, gene editing, cloud-based genomic analytics, and personalized medicine offer emerging opportunities.
About Us
Dimension Market Research (DMR) is a global market intelligence and consulting firm delivering data-driven insights that help organizations make informed strategic decisions. With expertise across 12+ industries and global markets, DMR provides syndicated reports, custom research, competitive analysis, white space analysis, and business strategy consulting.
Our research solutions combine analytical rigor, industry expertise, and forward-looking intelligence to identify opportunities, reduce risks, and support sustainable growth. Trusted by clients across diverse sectors, DMR is committed to delivering accurate, actionable insights that enable businesses to navigate evolving market landscapes with confidence.
Contact Us
Phone USA: +17323699777
Phone India: +919310023843
E-mail: enquiry@dimensionmarketresearch.com
Address USA: 957 Route 33, Suite 12 #308, Hamilton Square, NJ-08690
Address India: D44, Sector 6, Noida 201301, India
